Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2014-004002-15 | EudraCT Number |
Not provided
Not provided
Recruitment challenges despite several attenpts to increase enrollment
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to evaluate the inflammatory symptoms and signs (hyperemia, edema and pain) reduction after 24 hours of treatment with ketoprofen drops when associated to amoxicillin.
The total duration of the study period per patient is 10 ± 1 day
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ketoprofen + Amoxicillin | Experimental | Ketoprofen + Amoxicillin for 3 days, then Amoxicillin alone for 7 days |
|
| Amoxicillin | Placebo Comparator | Placebo (for ketoprofen) + Amoxicillin for 3 days, then Amoxicillin alone for 7 days |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ketoprofen | Drug | Formulation: oral solution 20mg/mL Route of administration: oral Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with reduction of inflammatory signs and symptoms after 24 hours of treatment | 24 hours |
| Measure | Description | Time Frame |
|---|---|---|
| Number of patients with reduction of inflammatory signs and symptoms after 72 hours of treatment | 72 hours | |
| Number of patients with reduction of inflammatory signs and symptoms with no use of rescue medication | 24 hours and 72 hours |
Not provided
Inclusion Criteria:
Quick-test positive for Streptococcus pyogenes;
Indication for treatment with amoxicillin according to labeling and physician's clinical evaluation;
Pain (for swallowing) evaluated by Wong Baker Faces Pain scale with at least grade 3;
Presence of at least two of the follow symptoms:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jaderson Lima, MD | Sanofi | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Sanofi-Aventis Administrative Office | São Paulo | Brazil |
Not provided
| ID | Term |
|---|---|
| D007660 | Ketoprofen |
| D000658 | Amoxicillin |
| ID | Term |
|---|---|
| D010666 | Phenylpropionates |
| D000146 | Acids, Carbocyclic |
| D002264 | Carboxylic Acids |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo (for Ketoprofen) | Drug | Formulation: oral solution Route of administration: oral Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d |
|
| Amoxicillin | Drug | Formulation: suspension 125mg/5 mL Route of administration: oral Dose regimen: 20-40mg/Kg/day administered t.i.d |
|
| Number of patients who used rescue medication after randomization. | 72 hours |
| D000667 |
| Ampicillin |
| D010400 | Penicillin G |
| D010406 | Penicillins |
| D047090 | beta-Lactams |
| D007769 | Lactams |
| D000577 | Amides |
| D013457 | Sulfur Compounds |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006571 | Heterocyclic Compounds |